RPGR gene therapy presents challenges in cloning the coding sequence
<p><strong>Introduction:</strong> Currently, there are three Phase I/II clinical trials based on gene therapy ongoing to test different AAV.RPGR or deleted RPGR vectors on patients affected by X-linked retinitis pigmentosa. These three vectors differ in the adeno-associated viral (...
| Main Authors: | , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
Taylor and Francis
2019
|